Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770411 | 0.88 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL770833 | 0.86 | DPP4 (0.39) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL770359 | 0.84 | DRD2 (0.37) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL15386644 | 0.83 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL770704 | 0.83 | KMT2A (0.49) | NPC1RAB9ASMN1; SMN2NPSR1POLB | |
| SCHEMBL770097 | 0.82 | KMT2A (0.48) | NPC1RAB9ASMN1; SMN2NPSR1POLB | |
| SCHEMBL770739 | 0.81 | HRH3 (0.45) | NPC1RAB9ASMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL770005 | 0.79 | HDAC4 (0.37) | RAB9ASMN1; SMN2TDP1QPCTCNR2 | |
| SCHEMBL772616 | 0.78 | EPHX2 (0.58) | SMN1; SMN2EPHX2FKBP1ATSHRALDH1A1 | |
| SCHEMBL770950 | 0.78 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2EPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.